Universität zu Köln

Heidegger, Isabel, Heidenreich, Axel and Pfister, David (2017). New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer. Target. Oncol., 12 (1). S. 37 - 46. DORDRECHT: SPRINGER. ISSN 1776-260X

Full text not available from this repository.

Abstract

Prostate cancer is the most common cancer in men. In recent years, several new targeted therapeutic agents for the treatment of metastatic castration resistant prostate cancer (mCRPC) have been developed. These include androgen receptor targeting agents, new taxanes, radium-223, and immunotherapies. In this short review, we provide a summary of clinical and preclinical biomarkers for each of these new treatment strategies, also including new markers currently presented in conference papers only. Moreover, we address the role of these biomarkers in clinical routine with the aim to select best-personalized treatment strategies for patients. Finally, we provide a decision tree for selecting the proper therapy for patients with mCRPC according to the discussed biomarkers.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Heidegger, Isabel UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, David UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-241339
DOI:	10.1007/s11523-016-0461-6
Journal or Publication Title:	Target. Oncol.
Volume:	12
Number:	1
Page Range:	S. 37 - 46
Date:	2017
Publisher:	SPRINGER
Place of Publication:	DORDRECHT
ISSN:	1776-260X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CIRCULATING TUMOR-CELLS; OVERCOMES ENZALUTAMIDE RESISTANCE; PROGRESSION-FREE SURVIVAL; RECEPTOR SPLICE VARIANTS; ACETATE PLUS PREDNISONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOCETAXEL CHEMOTHERAPY; SIPULEUCEL-T; PREDICTIVE BIOMARKER Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24133